Enhancing Treatment Durability with Second-Generation High-Dose Anti-VEGF Agents in Retinal Vascular Diseases

In this segment, Dr. Harit Bhatt and Dr. Deepak Sambhara explore the clinical promise of aflibercept 8 mg, the next-generation anti-VEGF therapy designed to enhance durability and maintain safety in managing wet AMD, DME, and RVO. Dr. Sambhara emphasizes that durability—the ability to extend treatment intervals without compromising outcomes—has become the “holy grail” in modern retina practice. He shares encouraging real-world experiences, noting that aflibercept 8 mg has enabled patients to extend dosing intervals more significantly than with first-generation agents, while preserving strong efficacy and safety. Dr. Bhatt echoes these observations, highlighting that “eight weeks is the new four weeks,” reflecting improved efficiency for both patients and clinicians. The discussion also covers safety reassurance regarding higher injection volumes, supported by real-world data, and enthusiasm for upcoming pre-filled syringe formulations, which promise to reduce variability, improve dosing accuracy, and streamline clinical workflow.